Scalper1 News
Top-rated biotech Medivation (MDVN) reported another round of successful trial results for its prostate-cancer drug Xtandi Thursday, giving the stock a brief bump in early trading. Medivation and its partner Astellas said that a midstage trial comparing Xtandi head-to-head with bicalutamide, better known as AstraZeneca’s (AZN) Casodex, showed a considerable survival benefit for the former in castration-resistant prostate cancer. The median Scalper1 News
Scalper1 News